Search results
Results from the WOW.Com Content Network
Although rosacea was first described by Guy de Chauliac in the 14th century and included Chaucer's The Canterbury Tales, [2] when the National Rosacea Society was founded in 1992 rosacea was still considered a rare disease, and its first approved treatment, topical metronidazole, received orphan drug designation by the U.S. Food and Drug Administration in the belief that fewer than 200,000 ...
Rosacea conglobata is a severe rosacea that can mimic acne conglobata, with hemorrhagic nodular abscesses and indurated plaques. [26] Phymatous rosacea is a cutaneous condition characterized by overgrowth of sebaceous glands. [11] Phyma is Greek for swelling, mass, or bulb, and these can occur on the face and ears. [26]: 693
The Royal Free Hampstead NHS Trust was authorised by Monitor as an NHS foundation trust on 1 April 2012, [9] subsequently changing its name to Royal Free London NHS Foundation Trust. [10] In the same month, University College London Hospitals NHS Foundation Trust took over management of Royal National Throat, Nose, and Ear Hospital from the ...
The NHS Connecting for Health (CFH) agency was part of the UK Department of Health and was formed on 1 April 2005, having replaced the former NHS Information Authority. It was part of the Department of Health Informatics Directorate, with the role to maintain and develop the NHS national IT infrastructure .
The NHS e-Referral Service (ERS) is an electronic referral system developed for the Health and Social Care Information Centre by IT consultancy BJSS. It is used by NHS England and it replaced the Choose and Book service on 15 June 2015. [ 1 ]
Persistent edema of rosacea (also known as chronic upper facial erythematous edema, Morbihan's disease or rosaceous lymphedema) is a hard, nonpitting edema found on the areas involved, those mainly being the forehead, glabella, upper eyelids, nose, and/or cheeks.
Any Qualified Provider (AQP) is a contractual system within the NHS internal market of the English National Health Service. The system was introduced under the Labour administration in 2009/10 under the name "Any Willing Provider" and was accelerated under the coalition Government which formed in 2010. In 2011 the name of the system was changed ...
The patient's consultant must apply to the fund using an application form supplied by NHS England. Decision Summaries which are the formal decisions of the Chemotherapy Clinical Reference Group are published. [5] Avastin is the most frequently requested treatment. Kadcyla is the most expensive drug funded.